Market Place
Sourcing Support
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
15 Feb 2024 //
GLOBENEWSWIRE
Elucida Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27 Dec 2023 //
GLOBENEWSWIRE
Elucida Oncology Presents Data from Phase 1/2 Study of ELU001
23 Oct 2023 //
GLOBENEWSWIRE
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO
11 Sep 2023 //
GLOBENEWSWIRE
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
24 Aug 2023 //
GLOBENEWSWIRE
Elucida Announces First Patient Dosed with ELU001 in Expansion of Ph 1/2 Trial
20 Jul 2023 //
GLOBENEWSWIRE
Elucida Oncology nabs more funds for its take on ADCs
23 Jun 2023 //
ENDPTS
Elucida Oncology Announces Positive Early Ph1 Safety Data Along Preclinical Data
20 Apr 2023 //
GLOBENEWSWIRE
Elucida to Present Clinical and Preclinical Data at the 2023 AACR Annual Meeting
11 Apr 2023 //
GLOBENEWSWIRE
Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare
03 Nov 2022 //
GLOBENEWSWIRE
Elucida Oncology to Present at Two Upcoming Conferences
03 Jun 2022 //
GLOBENEWSWIRE
Elucida Oncology to Present Trials in Progress Poster for PI/II Study of ELU001
01 Jun 2022 //
GLOBENEWSWIRE
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
06 May 2022 //
GLOBENEWSWIRE
Elucida Oncology`s ELU001 to Be Featured in Two Abstracts at the AACR
04 Apr 2022 //
GLOBENEWSWIRE
Elucida Oncology to Present at Two Upcoming Scientific Conferences
03 Mar 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.